U.S. Food and Drug Administration Approves Camzyos™
Bristol Myers Squibb, a member of Bio Nebraska, announced last week that the FDA approved Camzyos™ for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. Read more